Postulated release profile of recombinant human bone morphogenetic protein-2 (rhBMP-2) from demineralized dentin matrix
엄인웅, 구정귀, 이부규, 윤필영, 이정근, 남정훈,
소속 상세정보
엄인웅 ( Um In-Woong ) - Korea Tooth Bank R&D Department
구정귀 ( Ku Jeong-Kui ) - Seoul Asan Medical Center Department of Oral and Maxillofacial Surgery
이부규 ( Lee Bu-Kyu ) - Seoul Asan Medical Center Department of Oral and Maxillofacial Surgery
윤필영 ( Yun Pil-Young ) - Seoul National University Bundang Hospital Section of Dentistry Department of Oral and Maxillofacial Surgery
이정근 ( Lee Jeong-Keun ) - Ajou University School of Medicine Department of Oral and Maxillofacial Surgery
남정훈 ( Nam Jeong-Hun ) - Private Clinic Department of Dental Implant/Oral Surgery
Abstract
Demineralized dentin matrix (DDM) has been used as a recombinant human bone morphogenetic protein-2 (rhBMP-2) carrier in many clinical trials. To optimize the clinical safety and efficacy of rhBMP-2 with DDM, efforts have been made to improve the delivery of rhBMP-2 by 1) lowering the administered dose, 2) localizing the protein, and 3) prolonging its retention time at the action site as well as the bone forming capacity of the carrier itself. The release profile of rhBMP-2 that is associated with endogenous BMP in dentin has been postulated according to the type of incorporation, which is attributed to the loosened interfibrillar space and nanoporous dentinal tubule pores. Physically adsorbed and modified, physically entrapped rhBMP-2 is sequentially released from the DDM surface during the early stage of implantation. As DDM degradation progresses, the loosened interfibrillar space and enlarged dentinal tubules release the entrapped rhBMP-2. Finally, the endogenous BMP in dentin is released with osteoclastic dentin resorption. According to the postulated release profile, DDM can therefore be used in a controlled manner as a sequential delivery scaffold for rhBMP-2, thus sustaining the rhBMP-2 concentration for a prolonged period due to localization. In addition, we attempted to determine how to lower the rhBMP-2 concentration to 0.2 mg/mL, which is lower than the approved 1.5 mg/mL.
키워드
Collagen; Bone morphogenetic proteins; Demineralized dentin matrix
원문 및 링크아웃 정보
등재저널 정보